Cadrenal Therapeutics, Inc. (CVKD) Stock Price & Analysis
Cadrenal Therapeutics, Inc. (CVKD) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $1.69 (-1.74%), as of the Nov 19, 2026 trading session; market cap $6.97M.
Educational signal · not a buy or sell recommendation · How to read this
Cadrenal Therapeutics, Inc. · CVKD · NASDAQ
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Tecarfarin, a novel therapy for preventing systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. The company is headquartered in Ponte Vedra, Florida, and is currently managing a small team of employees.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cadrenal Therapeutics (CVKD)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a strained balance sheet, weak growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 4 reports
- Altman Z -21.76 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 27 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.69 | |
| Change on the day | -1.74% | |
| Market capitalisation | $6.97M | — |
| Price / earnings (trailing) | -0.85 | |
| Shares traded on the day | 36.7K |
Price & events
Other perspectives
Council score for Cadrenal Therapeutics (CVKD): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens disagrees with the Valuation pillar (Bubble, 2 of 100): it reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cadrenal Therapeutics (CVKD), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cadrenal Therapeutics, Inc. (CVKD) is listed on NASDAQ. It employs 5 people. The market values it at $6.97M.
What do the latest results show for Cadrenal Therapeutics (CVKD)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Cadrenal Therapeutics (CVKD)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -21.76 · Piotroski F 2. Trailing ratios: current ratio 6.26.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -21.76 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Cadrenal Therapeutics (CVKD)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -3.86 · 0 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for CVKD.
Checked against the records this page reads, on the dates shown above.
How does Cadrenal Therapeutics compare with its peers?
Short answer
Cadrenal Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Cadrenal Therapeutics (CVKD) — this page | $1.69 | $6.97M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $0.00
- EPS estimate
- $-3.86
Measured against a quoted price of $1.69 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CVKD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CVKD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cadrenal Therapeutics (CVKD)?
- Cadrenal Therapeutics Initiates Formal Strategic Process to Maximize Shareholder Value
- Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
- Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Common Questions About CVKD
These answers are editorial: 1 of these 9 answers is drawn from the CVKD research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CVKD?
CVKD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is CVKD a good stock to buy?
Stock Expert AI does not rate CVKD buy, sell or hold. Cadrenal Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CVKD stock price today?
The last price recorded for Cadrenal Therapeutics, Inc. (CVKD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about CVKD stock?
Given Cadrenal Therapeutics' early stage and limited analyst coverage, there is no widespread consensus on the stock. The company's value is primarily tied to the potential success of Tecarfarin.
What are the key factors to evaluate for CVKD?
Cadrenal Therapeutics, Inc. (CVKD) holds a MoonshotScore in the low range. However, the company's early stage and limited resources pose significant risks. Not financial advice.
How frequently does CVKD data refresh on this page?
CVKD's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CVKD's recent stock price performance?
Cadrenal Therapeutics, Inc. (CVKD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapy with orphan drug designation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CVKD overvalued or undervalued right now?
Cadrenal Therapeutics, Inc. (CVKD) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CVKD?
Fractional-share availability for Cadrenal Therapeutics, Inc. (CVKD) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com